nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

12.12.2018 | Original Article – Clinical Oncology

Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018)

verfasst von: Jianmin Xu, Jia Fan, Xinyu Qin, Jianqiang Cai, Jin Gu, Shan Wang, Xishan Wang, Suzhan Zhang, Zhongtao Zhang, China CRLM Guideline Group

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

The liver is the most common anatomical site for hematogenous metastases of colorectal cancer, and colorectal liver metastases is one of the most difficult and challenging points in the treatment of colorectal cancer. To improve the diagnosis and comprehensive treatment in China, the Guidelines have been edited and revised several times since 2008, including the overall evaluation, personalized treatment goals and comprehensive treatments, to prevent the occurrence of liver metastases, improve the resection rate of liver metastases and survival. The revised Guideline includes the diagnosis and follow-up, prevention, MDT effect, surgery and local ablative treatment, neoadjuvant and adjuvant therapy, and comprehensive treatment, and with advanced experience, latest results, detailed content, and strong operability.

Nur mit Berechtigung zugänglich

Adam R et al (2015) Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treatm Rev 41:729–741. https://doi.org/10.1016/j.ctrv.2015.06.006 CrossRef

Andre T et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116. https://doi.org/10.1200/JCO.2008.20.6771 CrossRefPubMed

Antoniou A et al (2007) Meta-analysis of clinical outcome after first and second liver resection for colorectal metastases. Surgery 141:9–18. https://doi.org/10.1016/j.surg.2006.07.045 CrossRefPubMed

Begin A et al (2014) Accuracy of preoperative automatic measurement of the liver volume by CT-scan combined to a 3D virtual surgical planning software (3DVSP). Surg Endosc 28:3408–3412. https://doi.org/10.1007/s00464-014-3611-x CrossRefPubMed

Bertens KA, Hawel J, Lung K, Buac S, Pineda-Solis K, Hernandez-Alejandro R (2015) ALPPS: challenging the concept of unresectability—a systematic review. Int J Surg 13:280–287. https://doi.org/10.1016/j.ijsu.2014.12.008 CrossRefPubMed

Brouquet A, Andreou A, Vauthey JN (2011) The management of solitary colorectal liver metastases. Surgeon 9:265–272. https://doi.org/10.1016/j.surge.2010.12.005 CrossRefPubMed

Cervantes A, Rosello S, Rodriguez-Braun E, Navarro S, Campos S, Hernandez A, Garcia-Granero E (2008) Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. Ann Oncol 19(Suppl 7):vii266–vii272. https://doi.org/10.1093/annonc/mdn438 CrossRefPubMed

Chang W et al (2016) Randomized controlled trial of intraportal chemotherapy combined with adjuvant chemotherapy (mFOLFOX6) for stage II and III colon cancer. Ann Surg 263:434–439. https://doi.org/10.1097/SLA.0000000000001374 CrossRefPubMed

Chau I, Chan S, Cunningham D (2003) Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. Clin Colorectal Cancer 3:19–33. https://doi.org/10.3816/CCC.2003.n.009 CrossRefPubMed

Coenegrachts K, De Geeter F, ter Beek L, Walgraeve N, Bipat S, Stoker J, Rigauts H (2009) Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol 19:370–379. https://doi.org/10.1007/s00330-008-1163-y CrossRefPubMed

de Jong MC et al (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250:440–448. https://doi.org/10.1097/SLA.0b013e3181b4539b CrossRefPubMed

Delbeke D, Martin WH (2004) PET and PET–CT for evaluation of colorectal carcinoma. Semin Nucl Med 34:209–223CrossRefPubMed

Esin E, Yalcin S (2016) Maintenance strategy in metastatic colorectal cancer: a systematic review. Cancer Treat Rev 42:82–90. https://doi.org/10.1016/j.ctrv.2015.10.012 CrossRefPubMed

Falcone A et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676. https://doi.org/10.1200/JCO.2006.09.0928 CrossRefPubMed

Folprecht G et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47. https://doi.org/10.1016/S1470-2045(09)70330-4 CrossRefPubMed

Foster JH (1984) Treatment of metastatic disease of the liver: a skeptic’s view. Semin Liver Dis 4:170–179. https://doi.org/10.1055/s-2008-1040656 CrossRefPubMed

Fraker DL, Soulen M (2002) Regional therapy of hepatic metastases. Hematol Oncol Clin N Am 16:947–967CrossRef

Grothey A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312. https://doi.org/10.1016/S0140-6736(12)61900-X CrossRefPubMed

Hur H et al (2009) Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197:728–736. https://doi.org/10.1016/j.amjsurg.2008.04.013 CrossRefPubMed

Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. https://doi.org/10.1056/NEJMoa032691 CrossRefPubMed

Iwamoto S et al (2014) Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer Res 34:1967–1973PubMed

Jones OM, Rees M, John TG, Bygrave S, Plant G (2005) Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br J Surg 92:1165–1168. https://doi.org/10.1002/bjs.4888 CrossRefPubMed

Kawaguchi Y et al (2014) Surgical resection for local recurrence after radiofrequency ablation for colorectal liver metastasis is more extensive than primary resection. Scand J Gastroenterol 49:569–575. https://doi.org/10.3109/00365521.2014.893013 CrossRefPubMed

Kemeny N et al (2005) Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23:4888–4896. https://doi.org/10.1200/JCO.2005.07.100 CrossRefPubMed

Koshariya M et al (2007) An update and our experience with metastatic liver disease. Hepatogastroenterology 54:2232–2239PubMed

Li J et al (2018) Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA J Am Med Assoc 319:2486–2496. https://doi.org/10.1001/jama.2018.7855 CrossRef

Mahnken AH, Pereira PL, de Baere T (2013) Interventional oncologic approaches to liver. metastases. Radiology 266:407–430. https://doi.org/10.1148/radiol.12112544 CrossRefPubMed

Mohiuddin M, Chen E, Ahmad N (1996) Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol 14:722–728. https://doi.org/10.1200/JCO.1996.14.3.722 CrossRefPubMed

Nordlinger B, Vauthey JN, Poston G, Benoist S, Rougier P, Van Cutsem E (2010) The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer 9:212–218. https://doi.org/10.3816/CCC.2010.n.031 CrossRefPubMed

Nosher JL, Ahmed I, Patel AN, Gendel V, Murillo PG, Moss R, Jabbour SK (2015) Non-operative therapies for colorectal liver metastases. J Gastrointest Oncol 6:224–240. https://doi.org/10.3978/j.issn.2078-6891.2014.065 CrossRefPubMedPubMedCentral

Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101:1033–1038. https://doi.org/10.1038/sj.bjc.6605259 CrossRefPubMedPubMedCentral

Okuno K (2007) Surgical treatment for digestive cancer. Current issues—colon cancer. Dig Surg 24:108–114. https://doi.org/10.1159/000101897 CrossRefPubMed

Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA (2007) Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11:860–868. https://doi.org/10.1007/s11605-007-0149-4 CrossRefPubMed

Poultsides GA et al (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27:3379–3384. https://doi.org/10.1200/JCO.2008.20.9817 CrossRefPubMedPubMedCentral

Primrose J et al (2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15:601–611. https://doi.org/10.1016/S1470-2045(14)70105-6 CrossRefPubMed

Ratti F et al (2015) Strategies to increase the resectability of patients with colorectal liver metastases: a multi-center case-match analysis of ALPPS and conventional two-stage hepatectomy. Ann Surg Oncol 22:1933–1942. https://doi.org/10.1245/s10434-014-4291-4 CrossRefPubMed

Rex DK et al (2006) Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer CA: a cancer. J Clin 56:160–167 (quiz 185–166)

Roxburgh CS, Richards CH, Moug SJ, Foulis AK, McMillan DC, Horgan PG (2012) Determinants of short- and long-term outcome in patients undergoing simultaneous resection of colorectal cancer and synchronous colorectal liver metastases. Int J Colorectal Dis 27:363–369. https://doi.org/10.1007/s00384-011-1339-9 CrossRefPubMed

Rusthoven KE et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572–1578. https://doi.org/10.1200/JCO.2008.19.6329 CrossRefPubMed

Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA, Lu D (2009) Local surgical, ablative, and radiation treatment of metastases CA: a cancer. J Clin 59:145–170. https://doi.org/10.3322/caac.20013 CrossRef

Tomlinson JS et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580. https://doi.org/10.1200/JCO.2007.11.0833 CrossRefPubMed

Topkan E, Onal HC, Yavuz MN (2008) Managing liver metastases with conformal radiation therapy. J Support Oncol 6:9–13, 15PubMed

Torres OJ, Moraes-Junior JM, Lima e Lima NC, Moraes AM (2012) Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): a new approach in liver resections. Braz Arch Dig Surg 25:290–292

Van Cutsem E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417. https://doi.org/10.1056/NEJMoa0805019 CrossRefPubMed

Van Cutsem E et al (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33:692–700. https://doi.org/10.1200/JCO.2014.59.4812 CrossRefPubMed

Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D (2003) Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg 90:956–962. https://doi.org/10.1002/bjs.4132 CrossRefPubMed

Wolpin BM, Mayer RJ (2008) Systemic treatment of colorectal cancer. Gastroenterology 134:1296–1310. https://doi.org/10.1053/j.gastro.2008.02.098 CrossRefPubMed

Xu J et al (2007) Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg 245:583–590. https://doi.org/10.1097/01.sla.0000250453.34507.d3 CrossRefPubMedPubMedCentral

Xu RH et al (2018) Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 19:660–671. https://doi.org/10.1016/s1470-2045(18)30140-2 CrossRefPubMed

Titel: Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018)
verfasst von: Jianmin Xu
Jia Fan
Xinyu Qin
Jianqiang Cai
Jin Gu
Shan Wang
Xishan Wang
Suzhan Zhang
Zhongtao Zhang
China CRLM Guideline Group
Publikationsdatum: 12.12.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2795-1

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018)

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database

Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment

ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study

Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer

Effects of metabolic syndrome on the prevalence of prostate cancer: historical cohort study using the national health insurance service database

Serum miR-16 as a potential biomarker for human cancer diagnosis: results from a large-scale population

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie